In the multivariate analysis, the absence of high blood pressure, greater number of preventive treatments at anti‐CGRP onset, and lower number of migraine days/month after anti‐CGRP treatment were independently associated with withdrawal of the treatment (p < 0.05). Here, CALCA is linked to migraine disorder.